Top

Published in:

01-11-2017 | Clinical Study

High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases

Authors: Mengxi Ge, Yingjie Zhuang, Xinli Zhou, Ruofan Huang, Xiaohua Liang, Qiong Zhan

Published in: Journal of Neuro-Oncology | Issue 2/2017

Abstract

Lung cancer is the leading cause of cancer death in men and women worldwide. Brain metastasis (BMs) of non-small cell lung cancer (NSCLC) is the most important cause of death. This study aimed to explore the association of epidermal growth factor receptor (EGFR) mutations and BMs in NSCLC. We analyzed 50 NSCLC patients with BMs and 50 match-paired NSCLC patients with no brain metastases (NBMs). The EGFR mutation status of primary lesions was detected using the amplification refractory mutation system polymerase chain reaction. The BMs patients had a higher frequency of EGFR mutations than the NBMs patients (52.0 vs. 22.0% respectively, P < 0.001), in both adenocarcinoma (60.5 vs. 30.6%, P = 0.003) and squamous carcinoma (37.5 vs. 0%, P = 0.04). The incidence of BMs in patients with EGFR mutations was higher than in patients with wild-type EGFR (70.3 vs. 38.1%, P = 002). NSCLC patients with BMs had a higher incidence of EGFR mutations and those with mutant EGFR had a higher frequency of BMs. EGFR mutations may promote brain metastasis growth of NSCLC.

Gril B, Evans L, Palmieri D, Steeg PS (2010) Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. Eur J Cancer 46(7):1204–1210. doi:10.1016/j.ejca.2010.02.033 CrossRefPubMedPubMedCentral

Zimm S, Wampler GL, Stablein D, Hazra T, Young HF (1981) Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 48(2):384–394CrossRefPubMed

Taillibert S, Le Rhun E (2015) [Epidemiology of brain metastases]. Cancer Radiother 19(1):3–9. doi:10.1016/j.canrad.2014.11.001 CrossRefPubMed

Peacock KH, Lesser GJ (2006) Current therapeutic approaches in patients with brain metastases. Curr Treat Options Oncol 7(6):479–489CrossRefPubMed

Won YK, Lee JY, Kang YN, Jang JS, Kang JH, Jung SL, Sung SY, Jo IY, Park HH, Lee DS, Chang JH, Lee YH, Kim YS (2015) Stereotactic radiosurgery for brain metastasis in non-small cell lung cancer. Radiat Oncol J 33(3):207–216. doi:10.3857/roj.2015.33.3.207 CrossRefPubMedPubMedCentral

Parlak C, Mertsoylu H, Guler OC, Onal C, Topkan E (2014) Definitive chemoradiation therapy following surgical resection or radiosurgery plus whole-brain radiation therapy in non-small cell lung cancer patients with synchronous solitary brain metastasis: a curative approach. Int J Radiat Oncol Biol Phys 88(4):885–891. doi:10.1016/j.ijrobp.2013.12.017 CrossRefPubMed

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735–742. doi:10.1016/S1470-2045(11)70184-X CrossRefPubMed

Huang Y, Zhang L, Shi Y, Ma S, Liao M, Bai C, Zhang Q, Wang C, Luo F, Yu S, Qin S, Zhi X, Zhou C (2015) Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study. Jpn J Clin Oncol 45(6):569–575. doi:10.1093/jjco/hyv036 CrossRefPubMed

Wu YL, Fukuoka M, Mok TS, Saijo N, Thongprasert S, Yang JC, Chu DT, Yang JJ, Rukazenkov Y (2013) Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. Lung Cancer 81(2):280–287. doi:10.1016/j.lungcan.2013.03.004 CrossRefPubMed

10.

Luo D, Ye X, Hu Z, Peng K, Song Y, Yin X, Zhu G, Ji Q, Peng Y (2014) EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases. Tumour Biol 35(3):2437–2444. doi:10.1007/s13277-013-1323-9 CrossRefPubMed

11.

Tomasini P, Serdjebi C, Khobta N, Metellus P, Ouafik L, Nanni I, Greillier L, Loundou A, Fina F, Mascaux C, Barlesi F (2016) EGFR and KRAS mutations predict the incidence and outcome of brain metastases in non-small cell lung cancer. Int J Mol Sci 17(12):2132. doi:10.3390/ijms17122132 CrossRefPubMedCentral

12.

Baek MY, Ahn HK, Park KR, Park HS, Kang SM, Park I, Kim YS, Hong J, Sym SJ, Park J, Lee JH, Shin DB, Cho EK (2016) Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Korean J Intern Med. doi:10.3904/kjim.2015.158

13.

Jin J, Zhou X, Liang X, Huang R, Chu Z, Jiang J, Zhan Q (2013) Brain metastases as the first symptom of lung cancer: a clinical study from an Asian medical center. J Cancer Res Clin Oncol 139(3):403–408. doi:10.1007/s00432-012-1344-6 CrossRefPubMed

14.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. doi:10.1002/ijc.29210 CrossRefPubMed

15.

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132. doi:10.3322/caac.21338 CrossRefPubMed

16.

Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284(1):31–53CrossRefPubMed

17.

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sanchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958–967. doi:10.1056/NEJMoa0904554 CrossRefPubMed

18.

Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A, Okinaga S, Nagashima M, Oizumi S, Uematsu K, Nagai Y, Moriyama G, Miyazawa H, Ikebuchi K, Morita S, Kobayashi K, Hagiwara K (2010) Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 126(3):651–655. doi:10.1002/ijc.24746 CrossRefPubMed

19.

Shin DY, Na II, Kim CH, Park S, Baek H, Yang SH (2014) EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol 9(2):195–199. doi:10.1097/JTO.0000000000000069 CrossRefPubMed

20.

Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Dartevelle P, Taranchon E, Besse B, Validire P, Italiano A, Soria JC (2009) Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol 4(10):1212–1220. doi:10.1097/JTO.0b013e3181b44321 CrossRefPubMed

21.

Zhang Q, Zhang X, Yan H, Jiang B, Xu C, Yang J, Chen Z, Su J, Wu YL, Zhou Q (2016) Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis. Thorac Cancer 7(6):648–654. doi:10.1111/1759-7714.12379 CrossRefPubMedPubMedCentral

22.

Jamal-Hanjani M, Spicer J (2012) Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res 18(4):938–944. doi:10.1158/1078-0432.CCR-11-2529 CrossRefPubMed

23.

Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C, Lee JS (2009) Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 65(3):351–354. doi:10.1016/j.lungcan.2008.12.011 CrossRefPubMed

Title: High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases
Authors: Mengxi Ge
Yingjie Zhuang
Xinli Zhou
Ruofan Huang
Xiaohua Liang
Qiong Zhan
Publication date: 01-11-2017
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2590-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis

Volumetric quantification of glioblastoma: experiences with different measurement techniques and impact on survival

Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide

Extraneuraxial metastases in medulloblastoma: is histology and molecular biology important?

Prediction of new brain metastases after radiosurgery: validation and analysis of performance of a multi-institutional nomogram

Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma